Key Highlights:

  • Phathom Pharmaceuticals shares fell 15.55% to $5.92 on October 23, 2026.
  • VOQUEZNA net revenue was $74.3 million in the second quarter, up 88% from $39.5 million.
  • The net loss narrowed to $17.6 million from $75.8 million a year earlier.
  • Cash stood at $182.5 million on June 30, 2026, against total liabilities of $671.3 million.
  • Third-quarter results and a webcast are scheduled for October 29, 2026.

Phathom Pharmaceuticals Stock: Are You Watching a 16% Drop With No Announced Catalyst?

Phathom Pharmaceuticals (NASDAQ:PHAT) shares fell 15.55% to $5.92 on Friday, October 23, 2026. The company has not announced a catalyst for the decline, and its most recent financial results date from July 30, 2026.

Phathom is a biopharmaceutical company focused on gastrointestinal diseases. It markets vonoprazan in the United States under the brand name VOQUEZNA.

The next scheduled event is a webcast on October 29, 2026, to report third-quarter results and provide a business update.

VOQUEZNA Sales: How Fast Is the Product Growing?

VOQUEZNA net revenue was $74.3 million in the second quarter of 2026, up 88% from $39.5 million a year earlier and up 27% from the first quarter. About 325,000 prescriptions were filled, up 88% year over year and 21% from the prior quarter.

Covered prescriptions accounted for about 209,000, or roughly 64% of the total. About 1.7 million total prescriptions had been filled as of July 17, 2026.

The company reported a net loss of $17.6 million, compared with $75.8 million a year earlier. Operating expenses fell to $63.1 million from $94.4 million.

Guidance Change: What Did the Company Lower in July?

On July 30, 2026, Phathom cut its 2026 net revenue guidance to $310 million to $325 million from $320 million to $345 million. The midpoint fell to $317.5 million from $332.5 million, a reduction of about 4.5% (calculated).

Non-GAAP operating expense guidance, excluding stock-based compensation, was narrowed to $235 million to $245 million from $235 million to $255 million. Gross-to-net guidance of 55% to 59% and gross margin of about 80% were unchanged.

The company still expects operating profitability excluding stock-based compensation. A law firm separately announced an investigation into securities claims involving Phathom in August 2026, according to a press release.

Balance Sheet: What Do Cash and Debt Look Like?

Cash was $182.5 million at June 30, 2026, up $1.6 million from March 31. Total liabilities were $671.3 million, and the stockholders' deficit was $344.3 million.

The company has a term loan and a revenue interest financing agreement, and quarterly interest expense was $15.1 million. Management said cash and future operating cash flow should be sufficient to meet debt obligations without additional debt or equity financing.

The release did not provide principal amounts for the debt.

Pipeline Milestones: What Is Expected in the Fourth Quarter?

Topline results from a Phase 2 trial in eosinophilic esophagitis are expected in the fourth quarter of 2026. The company also expects to enroll the first subject in a planned Phase 3 as-needed trial in non-erosive GERD in the same period.

What to Watch Next: Will Third-Quarter Results Show Growth Holding Up?

The takeaway from October 23, 2026 is that the shares fell sharply with no company-announced reason, after a quarter of fast revenue growth and a lowered revenue range. The next dated catalyst is the third-quarter report and webcast on October 29, 2026. Net revenue against the $310 million to $325 million range, prescription volumes and cash against the debt load are the main figures to follow.

Shares fell 15.55% to $5.92. The company has not announced a catalyst, and its latest results are from July 30, 2026.

The company guides net revenue of $310 million to $325 million, lowered from $320 million to $345 million in July.

The company will hold a webcast on October 29, 2026, at 8:00 a.m. EDT.